Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value
-
Published:2019-02
Issue:
Volume:43
Page:81-84
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Subject
General Medicine,Surgery
Reference41 articles.
1. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study;Finn;Lancet Oncol,2015
2. New math on drug cost-effectiveness;Bach;N Engl J Med,2015
3. Ribociclib as first-line therapy for HR-positive, advanced breast cancer;Hortobagyi;N Engl J Med,2016
4. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer;Goetz;J Clin Oncol,2017
5. Finn RS, Crown J, Lang I, et al: Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol 35:1001-1001, 2017
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献